Dodgy practices in biologics markets come under scrutiny
Biologic drug companies that make false comparisons with a biosimilar could get in trouble for violating both antitrust and consumer protection laws.
That was the message from Federal Trade Commission Chief...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch